Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

423
active users

med-mastodon.com: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#recombinant

0 posts0 participants0 posts today
Public
Giuseppe Michieli

Recent Molecular #Epidemiology of #Echovirus 11 Throughout North and West #Africa Resulted in the First Identification of a #Recombinant Strain from an Acute Flaccid #Paralysis Case in West Africa

Source: Viruses, AbstractEchovirus 11 has emerged as a major public health concern, causing sepsis in neonates in many European countries in recent years. In Africa, especially West Africa, where resources and diagnostic capacities are limited, only sporadic cases have been…

etidioh.wordpress.com/2024/11/

ETIDIoH · Recent Molecular #Epidemiology of #Echovirus 11 Throughout North and West #Africa Resulted in the First Identification of a #Recombinant Strain from an Acute Flaccid #Paralysis Case in West Africa
More from ETIDIoH
Public
Giuseppe Michieli

#Molecular basis of #pathogenicity of recently emerged #FCoV23 #coronavirus, BioRxIV: biorxiv.org/content/10.1101/20

FCoV-23 is a recently emerged, highly pathogenic #recombinant coronavirus responsible for a widespread #outbreak of #feline infectious #peritonitis (FIP) likely linked to in-host viral evolution. Here, we report cryoEM structures of two FCoV-23 spike (S) isoforms explaining that the in-host loss of domain 0 observed in clinical samples enhances entry into cells ...

bioRxiv · Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirusThe ability of coronaviruses to recombine and cross species barriers affects human and animal health globally and is a pandemic threat. FCoV-23 is a recently emerged, highly pathogenic recombinant coronavirus responsible for a widespread outbreak of feline infectious peritonitis (FIP) likely linked to in-host viral evolution. Here, we report cryoEM structures of two FCoV-23 spike (S) isoforms explaining that the in-host loss of domain 0 observed in clinical samples enhances entry into cells and fusogenicity by facilitating protease access, leading to biotype switching and lethality. We show that FCoV-23 can use several aminopeptidase N (APN) orthologs as receptors and reveal the molecular determinants of receptor species tropism, including a glycan modulating human receptor utilization. We define antigenic relationships among alphacoronaviruses infecting humans and other mammalian species and identify a cross-reactive alphacoronavirus monoclonal antibody inhibiting FCoV-23 pseudovirus entry, paving the way for vaccine and therapeutic development targeting this highly pathogenic virus. ### Competing Interest Statement N.P.K. and D.V. are named as inventors on patents for coronavirus nanoparticle vaccines filed by the University of Washington. N.P.K. is a paid consultant of Icosavax, Inc. and has received unrelated sponsored research agreements from Pfizer and GSK. J.D.B. is on the scientific advisory boards of Apriori Bio, Invivyd, and the Vaccine Company. JDB consults for GlaxoSmithKline.
Public
Giuseppe Michieli

#Efficacy of commercial #recombinant HVT #vaccines against a North #American clade 2.3.4.4b #H5N1 highly pathogenic avian #influenza virus in #chickens, PLOS One: journals.plos.org/plosone/arti

Both vaccines provided #protection from challenge to both types of chickens and ELLA-NI was sensitive at identifying #antibodies to the challenge virus therefore should be evaluated further for DIVA-VI.

journals.plos.orgEfficacy of commercial recombinant HVT vaccines against a North American clade 2.3.4.4b H5N1 highly pathogenic avian influenza virus in chickensThe outbreak of clade 2.3.4.4b H5 highly pathogenic avian influenza (HPAI) in North America that started in 2021 has increased interest in applying vaccination as a strategy to help control and prevent the disease in poultry. Two commercially available vaccines based on the recombinant herpes virus of turkeys (rHVT) vector were tested against a recent North American clade 2.3.4.4b H5 HPAI virus isolate: A/turkey/Indiana/22-003707-003/2022 H5N1 in specific pathogen free white leghorn (WL) chickens and commercial broiler chickens. One rHVT-H5 vaccine encodes a hemagglutinin (HA) gene designed by the computationally optimized broadly reactive antigen method (COBRA-HVT vaccine). The other encodes an HA gene of a clade 2.2 virus (2.2-HVT vaccine). There was 100% survival of both chicken types COBRA-HVT vaccinated groups and in the 2.2-HVT vaccinated groups there was 94.8% and 90% survival of the WL and broilers respectively. Compared to the 2.2-HVT vaccinated groups, WL in the COBRA-HVT vaccinated group shed significantly lower mean viral titers by the cloacal route and broilers shed significantly lower titers by the oropharyngeal route than broilers. Virus titers detected in oral and cloacal swabs were otherwise similar among both vaccine groups and chicken types. To assess antibody-based tests to identify birds that have been infected after vaccination (DIVA-VI), sera collected after the challenge were tested with enzyme-linked lectin assay-neuraminidase inhibition (ELLA-NI) for N1 neuraminidase antibody detection and by commercial ELISA for detection of antibodies to the NP protein. As early as 7 days post challenge (DPC) 100% of the chickens were positive by ELLA-NI. ELISA was less sensitive with a maximum of 75% positive at 10DPC in broilers vaccinated with 2.2-HVT. Both vaccines provided protection from challenge to both types of chickens and ELLA-NI was sensitive at identifying antibodies to the challenge virus therefore should be evaluated further for DIVA-VI.
Public
Giuseppe Michieli

#H6N2 #reassortant avian #influenza virus isolate in wild #birds in #Jiangxi Province, #China, Virus Genes: link.springer.com/article/10.1

The H6N2 isolate possessed a complex #genome, indicating it is a multi-gene #recombinant virus with genetic material from both #Eurasian and North #American #lineages.

SpringerLinkH6N2 reassortant avian influenza virus isolate in wild birds in Jiangxi Province, China - Virus GenesH6 avian influenza virus is widely prevalent in wild birds and poultry and has caused human infection in 2013 in Taiwan, China. During our active influenza surveillance program in wild waterfowl at Poyang Lake, Jiangxi Province, an H6N2 AIV was isolated and named A/bean goose/JiangXi/452-4/2013(H6N2). The isolate was characterized as a typical low pathogenic avian influenza virus (LPAIV) due to the presence of the amino acid sequence PQIETR↓GLFGAI at the cleavage site of the hemagglutinin (HA) protein. The genetic evolution analysis revealed that the NA gene of the isolate originated from North America and exhibited the highest nucleotide identity (99.29%) with a virus recovered from wild bird samples in North America, specifically A/bufflehead/California/4935/2012(H11N2). Additionally, while the HA and PB1 genes belonged to the Eurasian lineage, they displayed frequent genetic interactions with the North American lineage. The remaining genes showed close genetic relationships with Eurasian viruses. The H6N2 isolate possessed a complex genome, indicating it is a multi-gene recombinant virus with genetic material from both Eurasian and North American lineages.
Public
Giuseppe Michieli

#Recombinant A(#H6N1)-H274Y avian #influenza virus with dual #drug #resistance does not require permissive #mutations to retain the replicative #fitness in vitro and in ovo pubmed.ncbi.nlm.nih.gov/380862

PubMedRecombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo - PubMedThe possible emergence of drug-resistant avian flu raises concerns over the limited effectiveness of currently approved antivirals (neuraminidase inhibitors - NAIs) in the hypothetical event of a zoonotic spillover. Our study demonstrated that the recombinant avian A(H6N1) viruses showed reduced inh …
Public
DoomsdaysCW

So, note this... "analysis suggests the entirely new virus was created by an ECHV virus exchanging fragments of DNA with another virus, known as a ‘recombinant event’." I have been concerned that mucking around with #GM mosquitoes could cause new illness by combining DNA. There has been speculation about that being the case with #Zika.

Never-before-seen virus that causes malaria-like illness 'already circulating'

Story by Katherine Fidler, December 4, 2023

"A never-before-seen virus that causes a malaria-like illness has been detected in Peru.

"The disease was first seen in a man in his twenties, who went to hospital after suffering from two days of fever, chills, headaches and muscle pain among other symptoms.

"Doctors were unable to identify what was causing the mystery illness, but further laboratory investigation revealed a previously unknown pathogen."

msn.com/en-us/health/medical/n

www.msn.comMSN
#DNA#Recombinant#GMMosquitoes
Public
Protein Report

#Newswire: Icelandic molecular farming company ORF Genetics hf. and South Korean company SeaWith Inc. announce a partnership to boost the production of cell-cultured meat using ORF’s animal-free growth factors made from barley.

#cellbased #molecularfarming #recombinant #algae #microalgae #meat #protein #ingredients #biotech #foodtech #startups #innovation #iceland #korea #pressrelease

proteinreport.org/newswire/orf

Protein ReportORF Genetics and Seawith Enter into Partnership for Growth Factors and Cultivated Meat ProductionThe Icelandic ORF Genetics and the South Korean company SeaWith have announced a pioneering partnership to boost the production of cultivated meat using ORF’s MESOkine animal-free growth factors made from barley.
Public
Auscandoc

Safety and Immunogenicity of Spike Protein in and in India: A Phase 2-3 Randomized Clinical Trial | Vaccination | JAMA Pediatrics | JAMA Network jamanetwork.com/journals/jamap “SII-NVX-CoV2373 was safe and well tolerated in children and adolescents in this study. The vaccine was highly immunogenic and may be used in against COVID-19.”

jamanetwork.comSafety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in IndiaThis phase 2-3 randomized clinical trial evaluates the noninferiority of SII-NVX-CoV2373 in children and adolescents compared with adults and the safety of SII-NVX-CoV2373 compared with placebo.
Replied in thread
Public
Lorraine

@Njord
usually set my expectations very low as then happily surprised when it beats them…

however can only handle 1 year in advance at a time right now, as beyond that is too bleak

hope you’re right.
with every country on a mass infection plan, the #recombinant #variants are going to be off the hook bananas

people believe the “it’s getting milder” #misinformation which is unbelievable
this is sociopathy; preying on the gray space of plausible

Public *
Lorraine

nextstrain.org/staging/nextcla
i mean, instead of trying to slow this down, we’ve gone all in on mass infection #reinfection

NYC dropped its indoor mask mandates 3/2022 & most countries have followed suit including places like S. Korea that have been pretty cautious until now

what could possibly go wrong?🙄
#covidIsNotACold #covidIsNotOver #YouDoNotWantCovid #wearTheDamnMask you selfish a**holes🤬🤬 #sarscov2 #xbb #recombinant #viralsex #wtf

Overview of strains of Covid Phylogeny Clade ^ 21L 22A 22B 22C 22D Diversity 22E 22F 23A outgroup recombinant 20 30 40 50 60 70
Public
Philzilla℠

This doesn’t make good reading. #Recombinant strains that’ll keep #infection rates very high, & vaccinations having little impact on outcomes. #XBB1.15 is just the latest development in swarming #variants. thelancet.com/journals/laninf/

The Lancet Infectious DiseasesNeutralisation sensitivity of the SARS-CoV-2 XBB.1 lineageCo-infection with multiple SARS-CoV-2 lineages can result in recombination of the viral genomes and the emergence of novel, recombinant SARS-CoV-2 lineages.1–4 In January, 2022, the recombinant SARS-CoV-2 XBB lineage was first detected in India and incidence is increasing in Asia and Europe.5 The XBB lineage is the result of recombination of two omicron variant sublineages, BJ.1 and BM.1.1.1, and the breakpoint is located in the gene for the spike protein (appendix p 10),6 which is responsible for host cell entry and constitutes the target of neutralising antibodies.
Replied in thread
Public
Lorraine

@tomchappell @txwikinger
It’s been a #variant watch since the very beginning but in real earnest this year & idk where the origin of #sarscov2 spawned exactly from, but #China did everything it could to squelch it

R22 is on us, the rest of the world

There’s been over 600 mutations of #omicron alone just in the month of November 2022

#Delta could come back #recombinant or another old #variant

Skies the limit

Yet STILL NO #MASKMANDATE of N95 or better #stupidity

ExploreLive feeds
About